Suzuki, Kenshi
Wechalekar, Ashutosh D.
Kim, Kihyun
Shimazaki, Chihiro
Kim, Jin Seok
Ikezoe, Takayuki
Min, Chang-Ki
Zhou, Fude
Cai, Zhen
Chen, Xiaonong
Iida, Shinsuke
Katoh, Nagaaki
Fujisaki, Tomoaki
Shin, Ho-Jin
Tran, NamPhuong
Qin, Xiang
Vasey, Sandra Y.
Tromp, Brenda
Weiss, Brendan M.
Comenzo, Raymond L.
Kastritis, Efstathios
Funding for this research was provided by:
Janssen Research & Development, LLC
Article History
Received: 24 August 2022
Accepted: 31 December 2022
First Online: 2 March 2023
Declarations
:
: An independent ethics committee or institutional review board approved the trial. The study protocol was conducted in accordance with the principals of the Declaration of Helsinki and the International Conference on Harmonisation guidelines on Good Clinical Practice.
: All patients provided written informed consent.
: KS consulted for and received honoraria and research funding from Celgene and Amgen; consulted for and received honoraria from Takeda and Janssen; received honoraria and research funding from Bristol Myers Squibb; and received honoraria from Ono, Novartis, Sanofi, and AbbVie. ADW received honoraria from and served on a board of directors or advisory committees for Janssen, Takeda, Caelum, and Celgene. KK consulted for and received honoraria and research funding from Bristol Myers Squibb, Takeda, Amgen, Celgene, and Janssen. CS received honoraria from Sanofi, Bristol Myers Squibb, and Janssen. FZ is currently employed by Peking University First Hospital. SI received honoraria and research funding from Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Takeda, Ono, Celgene, and Janssen; and received research funding from Merck, AbbVie, Kyowa Kirin, and Chugai. NK received honoraria from Janssen. NT, SYV, and BT are current employees of Janssen and hold equity in Johnson & Johnson. XQ is a current employee of Janssen. BMW was an employee of Janssen at the time of the study. RLC consulted for and received research funding from Prothena, Janssen, Takeda, and Karyopharm and consulted for Amgen, Sanofi, Unum, and Caelum. EK consulted for and received honoraria and research funding from Janssen and Amgen; consulted for and received honoraria from Genesis and Takeda; was reimbursed by Janssen, Genesis, and Takeda for travel, accommodations, and expenses; and consulted for Pfizer. JSK, TI, C-KM, ZC, XC, TF, H-JS, and JL had no relevant conflicts of interest to disclose.